Lundbeck's alcohol dependence drug approved in Europe
This article was originally published in Scrip
Executive Summary
Lundbeck's alcohol dependence treatment Selincro (nalmefene) has been approved by the European Commission. Anders Gersel Pedersen, head of R&D at Lundbeck, told Scrip that the real discussions about reimbursement of Selincro across Europe start now. "The feedback we have had so far is that there is a high level of interest. There is a clear recognition in many countries that this is a serious problem, and that this is an interesting approach to tackle it. They are positive about [Selincro] conceptually."